Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4
study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected
participants with selected infection types (Hospital Acquired Pneumonia [HAP] (including
Ventilator-Associated Pneumonia [VAP]); Complicated Urinary-Tract Infection [cUTI];
Complicated Intra-Abdominal Infection [cIAI]; Bloodstream Infection [BSI]) due to
carbapenem-resistant Gram-negative pathogens in China.This study will be an estimation study.
The statistical inference will be based on point estimate and confidence interval.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Avibactam Avibactam, ceftazidime drug combination Ceftazidime